Disclosures
About this publication
BioBoyScout publishes independent investment research authored by Robert Toczycki, JD, MBA. The publication focuses on RNAi therapeutics, platform biology, and biotech mergers and acquisitions, with particular depth on Arrowhead Pharmaceuticals (NASDAQ: ARWR) and the broader gene-silencing competitive landscape.
BioBoyScout is not a registered investment advisor, broker-dealer, research firm, or fiduciary. Robert Toczycki is an independent investor writing about his own analysis, his own portfolio, and his own views.
Position disclosure
The author maintains a long position in Arrowhead Pharmaceuticals (ARWR) and has held this position prior to and throughout the publication of all BioBoyScout research. The author may also hold positions — long or short, directly or through derivatives — in other companies discussed on this publication, including but not limited to Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Wave Life Sciences (WVE), ImmunityBio (IBRX), and Biogen (BIIB).
The author may add to, reduce, or close any position at any time, without notice and without updating prior published research to reflect the change.
Position disclosure specific to a given paper or post will be noted at the bottom of that piece where material.
Not investment advice
Nothing published on BioBoyScout — including white papers, posts, notes, replies, charts, valuation frameworks, or commentary — constitutes investment advice, a recommendation to buy, sell, or hold any security, or a solicitation of any kind. Content is published for informational and educational purposes only and reflects the author’s personal analysis and opinions as of the date of publication.
Investment decisions should be made only after consultation with a licensed financial advisor and independent due diligence. Readers are solely responsible for their own investment decisions and outcomes.
Sources and accuracy
BioBoyScout draws on publicly available sources including SEC filings, company presentations, peer-reviewed scientific literature, conference proceedings, sell-side research, news coverage, and conversations with industry participants where appropriate. The author makes a good-faith effort to ensure factual accuracy at the time of publication but does not guarantee the completeness, accuracy, or timeliness of any information. Information may become outdated, and the author has no obligation to update prior research.
Forward-looking statements — including projections of clinical outcomes, regulatory decisions, deal valuations, and market dynamics — are inherently uncertain and reflect the author’s opinion only.
Compensation and conflicts
The author has not received and does not accept compensation from any company, asset manager, investment bank, fund, or third party in exchange for coverage, mention, or favorable treatment in BioBoyScout research. The author does not participate in paid promotions, sponsored content, or stock promotion of any kind.
If this changes — for example, if the author accepts a sponsored post, paid consulting engagement, or affiliate arrangement — it will be disclosed prominently in the relevant piece and updated here.
The author has professional relationships with individuals at companies covered, including Arrowhead Pharmaceuticals. These relationships are arms-length, do not involve material non-public information, and do not influence the editorial independence of published research.
No fiduciary relationship
Subscription to BioBoyScout — free or paid — does not create an advisory, fiduciary, or client relationship between the reader and the author. Communication via comments, email, chat, or direct message is informational only and is not investment advice.
Forward-looking caution
Statements about the future — including but not limited to clinical trial outcomes, regulatory approvals, acquisition probabilities, valuations, competitive positioning, and market sizing — are forward-looking and subject to substantial risk and uncertainty. Actual results may differ materially. Past performance is not indicative of future results.
Contact
Questions, corrections, or material concerns about disclosures: bioboyscout@gmail.com
Last updated: May 2026